Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio.

Ayrmid has offered to buy bluebird for $4.5-apiece upfront, plus a one-time contingent value right (CVR) of $6.84 per share tied to a sales milestone, bluebird said Friday.